Literature DB >> 17008686

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

Rangaswamy Govindarajan, Josna Adusumilli, Donna L Baxter, Anthony El-Khoueiry, Sami I Harik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008686     DOI： 10.1200/JCO.2006.08.4608

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Reversible posterior leukoencephalopathy syndrome and trastuzumab.

Authors:  Hiroyasu Kaneda; Isamu Okamoto; Taroh Satoh; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2011-06-03       Impact factor: 3.850

Review 2.  Neurotoxicity of biologically targeted agents in pediatric cancer trials.

Authors:  Elizabeth M Wells; Amulya A Nageswara Rao; Joseph Scafidi; Roger J Packer
Journal:  Pediatr Neurol       Date:  2012-04       Impact factor: 3.372

3.  Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma.

Authors:  Liesbeth M Kager; Marie-Jose Kersten; Raoul Peter Kloppenborg; Rien Van Oers; Bert-Jan Van den Born
Journal:  BMJ Case Rep       Date:  2009-10-12

4.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

5.  Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.

Authors:  Erkan Dogan; Sercan Aksoy; Cagatay Arslan; Didem S Dede; Kadri Altundag
Journal:  Med Oncol       Date:  2010-12       Impact factor: 3.064

Review 6.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

Review 7.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

Review 8.  Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Authors:  Richard G Abramson; Vandana G Abramson; Emily Chan; Leora Horn; Vicki L Keedy; William Pao; Jeffrey A Sosman
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

9.  A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors:  R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal:  Gynecol Oncol       Date:  2013-01-13       Impact factor: 5.482

10.  Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Authors:  Michael L Maitland; George L Bakris; Henry R Black; Helen X Chen; Jean-Bernard Durand; William J Elliott; S Percy Ivy; Carl V Leier; Joann Lindenfeld; Glenn Liu; Scot C Remick; Richard Steingart; W H Wilson Tang
Journal:  J Natl Cancer Inst       Date:  2010-03-29       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.